IGM BIOSCIENCES, INC. (IGMS) News
Filter IGMS News Items
IGMS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IGMS News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest IGMS News From Around the Web
Below are the latest news stories about IGM BIOSCIENCES INC that investors may wish to consider to help them evaluate IGMS as an investment opportunity.
IGM Biosciences downgraded to Hold from Buy at JefferiesJefferies downgraded IGM Biosciences (IGMS) to Hold from Buy with a price target of $2, down from $48, after the company discontinued all clinical development of drugs in its autoimmune franchise and said it is evaluating internal options and strategic alternatives with the goal of maximizing value for its shareholders. Following the announcement, the firm removed clinical program revenue from its model and lowered its view of platform value to $50M, mostly related to the still-ongoing Sanofi (S |
IGM Biosciences Shares Drop 68% as Company Halts Key Programs and Cuts WorkforceThe company is reducing its workforce by 73% and evaluating strategic alternatives to preserve shareholder value. |
IMG Biosciences enacts massive lay-offs after Phase I trial failureFollowing the negative Phase I trial outcome for its autoimmune disease treatment, the company is cutting 73% of jobs. |
IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs– Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Company reducing its workforce by 73% – – Cash and investments of $183.8 million (unaudited) as of December 31, 2024 – MOUNTAIN VIEW, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company committed to developing and delivering medicines to treat patients with autoimmune and inflammatory diseases, today announced a strategic update to halt further develop |
IGM’s autoimmune pivot backfires as top drug disappoints in testingThe biotech will stop developing two drugs and lay off much of its staff after its lead therapy wasn’t as potent in early testing as the company expected. |
IGM Biosciences Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsIGM Biosciences ( NASDAQ:IGMS ) Third Quarter 2024 Results Key Financial Results Net loss: US$61.4m (flat on 3Q 2023... |
IGM Biosciences, Inc. (IGMS) Reports Q3 Loss, Tops Revenue EstimatesIGM Biosciences (IGMS) delivered earnings and revenue surprises of -23.17% and 123.38%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update– Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 – – IGM-2644 (CD38 x CD3) expected to enter clinical study for generalized myasthenia gravis by year-end 2024 – – Cash runway expected to fund operations into 2027 – MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies |
IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, IGM Biosciences... |
IGM Biosciences to Present at Three Upcoming Investor ConferencesMOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management will present at three upcoming investor conferences: Guggenheim Healthcare Innovation Conference on Monday, November 11 at 11:30 a.m. EST in BostonStifel Healthcare Conference on Tuesday, November 19 at 12:40 p.m. EST in New YorkJefferies London Healthcare Conference on Thursday, No |